YY1 and glioblastoma: Hence, as anti-cancer immunotherapy has gained momentum with the development of new immunotherapeutic strategies approved by the FDA for various cancers, targeting YY1 in combination with these new approved immunotherapies should result in an effective treatment of the GBM.